Sickle Cell Anemia Testing & Screening Market Size, Share, Growth, Industry Analysis, Trends and Dynamics, By Types (Hemoglobin Electrophoresis, High-performance Liquid Chromatography (HPLC), Point-of-Care Tests, Other Test), By Applications (Newborn Screening (12 months and below), Adult Screening (25 to 60 years), Other Age Groups (1 to 25 & above 60 years), and Regional Insights and Forecast to 2035

Sickle Cell Anemia Testing & Screening Market Size

Global Sickle Cell Anemia Testing & Screening Market size was USD 294.57 Million in 2025 and is projected to touch USD 314.41 Million in 2026, USD 334.25 Million in 2027 to USD 579.75 Million by 2035, exhibiting a CAGR of 6.31% during the forecast period [2026-2035].

The Sickle Cell Anemia Testing & Screening Market is expanding as healthcare systems place greater focus on early diagnosis, newborn screening, carrier identification, and better disease monitoring. Screening programs account for an estimated 40% of testing demand, while diagnostic testing and follow-up testing contribute about 60%. Growing awareness is supporting wider use of blood-based screening methods, with laboratory testing representing more than 70% of routine testing activity in many established healthcare settings. Demand is also being supported by genetic counseling, family screening, and improved access to specialized diagnostic services.

The U.S. Sickle Cell Anemia Testing & Screening Market is supported by established newborn screening programs, advanced laboratories, and growing demand for accurate genetic and blood-based testing. Newborn and early-life screening represents nearly 45% of testing activity, while diagnostic and confirmatory testing contributes around 55%. Molecular testing adoption is estimated at more than 30% in specialized settings, while conventional blood-based methods remain widely used because of their lower cost and broad laboratory availability. Increasing awareness among healthcare providers is also supporting earlier patient identification.

Key Findings

• Market Size: USD 294.57 Million in 2025, USD 314.41 Million in 2026, USD 579.75 Million by 2035, with a CAGR of 6.31%.
• Growth Drivers: Screening awareness reaches 40%, newborn testing 45%, laboratory adoption 70%, and genetic testing demand exceeds 30%.
• Trends: Early screening exceeds 40%, molecular testing adoption surpasses 30%, automated workflows approach 35%, and digital reporting exceeds 25%.
• Top Key Players: STRECK, INC., BioMedomics Inc., Laboratory Corporation of America Holdings, Silver Lake Research Corporation & HEMEX HEALTH.
• Regional Insights: North America holds 35%, Europe 25%, Asia-Pacific 28%, and Rest of the World 12% of the overall market.
• Challenges: Limited screening access affects about 35% of underserved populations, while testing awareness gaps approach 30% and specialist shortages exceed 25%.
• Industry Impact: Early testing can support 40% faster identification, improve care planning by 35%, and increase follow-up testing by 30%.
• Recent Developments: Molecular methods exceed 30% adoption in advanced laboratories, automation approaches 35%, and digital reporting improves workflow efficiency by 25%.

Unique market activity is being shaped by wider newborn screening, increased carrier testing, improved laboratory methods, and stronger demand for rapid identification of sickle cell traits and disease. Healthcare providers are placing greater emphasis on reliable screening before symptoms become severe. Blood-based methods continue to hold a major role because they are accessible and familiar to laboratories, while molecular and genetic methods are gaining importance in confirmatory testing, complex cases, and family screening programs.

Sickle Cell Anemia Testing & Screening Market Trends

The Sickle Cell Anemia Testing & Screening Market is seeing strong interest in early diagnosis, newborn testing, carrier identification, and faster laboratory workflows. Newborn screening represents approximately 45% of routine screening demand, while follow-up and confirmatory testing account for about 55%. Laboratory-based testing continues to represent more than 70% of overall testing activity because of its established use and broad availability. Molecular and genetic methods are gaining attention, with adoption estimated above 30% in advanced diagnostic centers. Around 40% of testing demand is linked to early identification and preventive care needs.

Another important trend is the wider use of automated laboratory systems and improved test interpretation. Automated workflows account for nearly 35% of activity in advanced laboratories, helping reduce manual work and improve result consistency. Point-of-care and rapid testing methods represent more than 20% of testing activity in selected settings where laboratory access is limited. Family screening contributes about 30% of demand in programs focused on carrier identification. More than 40% of healthcare providers increasingly prioritize early testing for people with relevant family history or risk factors.

Sickle Cell Anemia Testing & Screening Market Dynamics

OPPORTUNITY

"Expansion of early screening programs"

The expansion of newborn and family screening creates a major opportunity for the Sickle Cell Anemia Testing & Screening Market. Newborn screening accounts for about 45% of screening activity, while family and carrier testing contribute nearly 30%. Wider healthcare access, community awareness, and genetic counseling can increase testing coverage, particularly in underserved populations where screening gaps remain above 30%.

DRIVERS

"Rising demand for early diagnosis"

Early diagnosis is a key driver for the Sickle Cell Anemia Testing & Screening Market. Nearly 40% of testing demand is connected with early identification and preventive care. Laboratory-based methods represent more than 70% of routine testing, while molecular testing exceeds 30% adoption in specialized centers. Increased awareness among healthcare providers is further supporting earlier testing and follow-up.

RESTRAINTS

"Limited access to advanced testing"

Limited access to specialized diagnostic services remains a restraint for the Sickle Cell Anemia Testing & Screening Market. Testing access gaps affect more than 30% of underserved populations in some settings, while advanced molecular testing availability remains below 40% in resource-limited laboratories. High equipment needs, trained staff shortages, and uneven healthcare coverage can slow wider adoption of advanced screening methods.

CHALLENGE

"Testing awareness and laboratory capacity"

The Sickle Cell Anemia Testing & Screening Market faces challenges from uneven awareness, limited laboratory capacity, and differences in testing quality. Awareness gaps affect nearly 30% of at-risk communities, while specialist shortages exceed 25%. More than 35% of smaller healthcare facilities may face limitations in advanced confirmation testing, creating delays in diagnosis and referral.

Segmentation Analysis

The Sickle Cell Anemia Testing & Screening Market is segmented by testing method and application, with each segment serving a different diagnostic need. The global market was valued at USD 294.57 Million in 2025 and is projected to reach USD 314.41 Million in 2026 and USD 579.75 Million by 2035, at a CAGR of 6.31%. Hemoglobin Electrophoresis remains widely used for routine diagnosis, while HPLC supports detailed hemoglobin analysis. Point-of-Care Tests are gaining attention because they offer faster results, while newborn screening remains a major application due to the value of early disease identification.

By Type

Hemoglobin Electrophoresis

Hemoglobin Electrophoresis is an established testing method in the Sickle Cell Anemia Testing & Screening Market and is widely used to identify different hemoglobin types. It represents about 32% of the type segment, supported by broad laboratory use, familiar testing procedures, and its role in confirming abnormal hemoglobin patterns. Hospitals, diagnostic laboratories, and specialist centers continue to use this method for routine screening and confirmation.

Hemoglobin Electrophoresis generated approximately USD 94.26 Million in 2025, representing 32% of the Sickle Cell Anemia Testing & Screening Market, and this segment is expected to expand at a CAGR of approximately 5.9%, supported by routine diagnostic demand, laboratory availability, and continued use in confirmatory testing.

High-performance Liquid Chromatography (HPLC)

High-performance Liquid Chromatography (HPLC) is an important segment because it provides detailed separation and measurement of hemoglobin variants. The method accounts for approximately 27% of the type segment and is used by laboratories seeking reliable and detailed results. HPLC is particularly useful where laboratories handle higher testing volumes. Increased laboratory automation and demand for consistent results are supporting adoption.

High-performance Liquid Chromatography generated approximately USD 79.53 Million in 2025, representing 27% of the Sickle Cell Anemia Testing & Screening Market, with an estimated CAGR of 6.6%, supported by laboratory automation, higher testing volumes, improved result consistency, and demand for detailed hemoglobin analysis.

Point-of-Care Tests

Point-of-Care Tests are gaining importance because they can provide screening results closer to patients and can support testing in locations with limited laboratory access. This segment accounts for nearly 24% of the type segment. Demand is linked to faster screening, community healthcare programs, and the need for simple testing workflows. Point-of-Care Tests can be especially useful in remote and underserved areas where laboratory infrastructure is limited, helping expand access to Sickle Cell Anemia Testing & Screening Market services.

Point-of-Care Tests generated approximately USD 70.70 Million in 2025, representing 24% of the Sickle Cell Anemia Testing & Screening Market, and are expected to grow at a CAGR of approximately 7.2%, supported by rapid testing demand, decentralized healthcare, easier workflows, and wider screening access.

Other Test

Other Test methods include additional laboratory and specialized approaches used when routine screening requires further assessment. This segment accounts for around 17% of the type segment and includes testing approaches used for confirmation, complex cases, and specialized diagnostic needs. Demand is supported by increasing use of genetic analysis, confirmatory testing, and personalized diagnostic pathways. As laboratories expand their testing capabilities, these methods are expected to remain useful for patients requiring more detailed evaluation.

Other Test methods generated approximately USD 50.08 Million in 2025, representing 17% of the Sickle Cell Anemia Testing & Screening Market, with an estimated CAGR of 5.4%, driven by specialized testing demand, confirmatory diagnosis, genetic analysis, and complex patient assessment.

By Application

Newborn Screening (12 months and below)

Newborn Screening is a leading application in the Sickle Cell Anemia Testing & Screening Market because early identification can support timely medical care and family counseling. The segment represents approximately 45% of application demand. Screening during early life helps identify affected infants before serious complications develop. Healthcare systems are placing greater focus on universal or targeted newborn screening, while improved laboratory coordination and follow-up programs are helping increase testing coverage and support early intervention.

Newborn Screening generated approximately USD 132.56 Million in 2025, representing 45% of the Sickle Cell Anemia Testing & Screening Market, with an estimated CAGR of 7.0%, supported by early diagnosis programs, newborn healthcare expansion, family counseling, and stronger screening coverage.

Adult Screening (25 to 60 years)

Adult Screening represents around 25% of application demand and is important for individuals who were not screened earlier, people with an unknown carrier status, and adults requiring diagnostic confirmation. The segment is supported by greater awareness of inherited blood disorders and increasing interest in family-based testing. Adult screening can also support reproductive planning and genetic counseling. Hospitals, diagnostic laboratories, and specialist centers remain important providers of adult screening services.

Adult Screening generated approximately USD 73.64 Million in 2025, representing 25% of the Sickle Cell Anemia Testing & Screening Market, with an estimated CAGR of 5.8%, driven by greater disease awareness, carrier identification, family testing, reproductive planning, and diagnostic follow-up.

Other Age Groups (1 to 25 & above 60 years)

Other Age Groups account for approximately 30% of application demand and include children, young adults, and older individuals requiring screening or confirmatory testing. Testing in these groups can be linked to symptoms, family history, carrier identification, or follow-up care. Growing awareness of inherited blood disorders is encouraging more people to seek testing outside standard newborn programs. Diagnostic laboratories and hospitals continue to support this segment through routine and specialized testing services.

Other Age Groups generated approximately USD 88.37 Million in 2025, representing 30% of the Sickle Cell Anemia Testing & Screening Market, with an estimated CAGR of 6.0%, supported by family screening, carrier identification, diagnostic follow-up, and wider awareness across age groups.

Sickle Cell Anemia Testing & Screening Market Regional Outlook

The global Sickle Cell Anemia Testing & Screening Market was valued at USD 294.57 Million in 2025 and is projected to reach USD 314.41 Million in 2026 and USD 579.75 Million by 2035, expanding at a CAGR of 6.31%. North America holds the largest regional share at 35%, followed by Asia-Pacific at 28%, Europe at 25%, and Middle East & Africa at 12%. Regional demand is shaped by newborn screening programs, laboratory infrastructure, disease awareness, healthcare access, and the adoption of advanced diagnostic methods.

North America

North America holds approximately 35% of the global Sickle Cell Anemia Testing & Screening Market, making it the leading regional segment. The region benefits from established newborn screening programs, strong laboratory networks, and wider access to specialized testing. Newborn screening contributes nearly 45% of regional testing activity, while laboratory-based methods account for more than 70%. Molecular and genetic testing adoption is above 30% in specialized centers. Demand is also supported by family screening, carrier identification, genetic counseling, and improved follow-up systems. The United States represents the major demand center, while Canada contributes through organized screening and diagnostic services. Automation is increasingly used in larger laboratories, with automated workflows approaching 35% of advanced testing activity.

North America represents approximately USD 110.04 Million in 2026, accounting for nearly 35% of the Sickle Cell Anemia Testing & Screening Market. Strong newborn screening coverage, advanced diagnostic laboratories, healthcare awareness, and access to confirmatory testing support regional demand.

Regulatory and public-health support plays an important role through bodies such as the U.S. Food and Drug Administration, Centers for Disease Control and Prevention, and relevant national and provincial health authorities. These organizations support diagnostic quality, screening standards, laboratory practices, and public-health testing programs.

Europe

Europe accounts for approximately 25% of the Sickle Cell Anemia Testing & Screening Market and benefits from structured healthcare systems and established diagnostic laboratory networks. Newborn and early-life testing contributes around 40% of regional screening activity, while family and carrier screening account for nearly 30%. Demand is also supported by migration, genetic counseling, and greater awareness of inherited blood disorders. Molecular testing adoption exceeds 25% in advanced diagnostic centers, while conventional laboratory methods remain widely used. Healthcare providers are increasingly focused on early identification and coordinated follow-up. Digital reporting and laboratory automation are also expanding, with automated workflows approaching 30% in larger diagnostic facilities.

Europe represents approximately USD 78.60 Million in 2026, accounting for nearly 25% of the Sickle Cell Anemia Testing & Screening Market. Strong healthcare infrastructure, organized screening pathways, laboratory quality systems, and increased awareness of inherited blood disorders support regional growth.

Regulatory support is influenced by bodies and frameworks including the European Medicines Agency, European Commission, and national health authorities. Their roles include supporting diagnostic quality, patient safety, laboratory standards, and healthcare testing practices across European markets.

Asia-Pacific

Asia-Pacific represents approximately 28% of the Sickle Cell Anemia Testing & Screening Market and offers strong opportunities because of its large population base and expanding healthcare access. The region accounts for about 30% of global screening demand in emerging healthcare settings, while newborn and early-life testing continues to gain importance. Point-of-Care Tests represent more than 20% of testing activity in selected areas where laboratory access is limited. Molecular testing is expanding in major urban centers, while conventional blood-based testing remains common. Government screening initiatives, improving diagnostic infrastructure, and rising awareness are encouraging wider testing coverage. India, China, Japan, Australia, and other regional markets show different levels of testing maturity, creating demand for both basic and advanced diagnostic methods.

Asia-Pacific represents approximately USD 88.03 Million in 2026, accounting for nearly 28% of the Sickle Cell Anemia Testing & Screening Market. Expanding healthcare infrastructure, large patient populations, growing awareness, community screening, and improved laboratory access support regional demand.

Regulatory support varies across the region and includes national health ministries, medical device regulators, laboratory accreditation bodies, and public-health agencies. These authorities support diagnostic quality, product approvals, laboratory standards, screening programs, and safe use of testing technologies.

Middle East & Africa

Middle East & Africa accounts for approximately 12% of the Sickle Cell Anemia Testing & Screening Market and presents significant opportunities linked to improved screening coverage and healthcare access. Family screening and newborn testing are important demand areas, together representing more than 60% of testing activity in several screening-focused programs. Point-of-Care Tests are gaining value in areas where laboratory infrastructure is limited, with decentralized testing exceeding 20% of activity in selected settings. Awareness programs, genetic counseling, community health initiatives, and better referral systems are supporting market development. However, uneven laboratory capacity, trained staff shortages, and differences in healthcare access remain important barriers. Expansion of diagnostic centers and public-health screening can improve testing reach across the region.

Middle East & Africa represents approximately USD 37.73 Million in 2026, accounting for nearly 12% of the Sickle Cell Anemia Testing & Screening Market. Expanding screening access, community healthcare programs, increasing awareness, and greater use of decentralized testing support regional opportunities.

Regulatory support is provided through national ministries of health, public-health authorities, medical device regulators, and laboratory accreditation organizations. Their responsibilities include laboratory quality, diagnostic oversight, screening policies, product registration, and public-health testing standards.

List of Key Sickle Cell Anemia Testing & Screening Market Companies Profiled

Investment Analysis and Opportunities

Investment activity in the Sickle Cell Anemia Testing & Screening Market is increasingly focused on early diagnosis, rapid testing, molecular methods, laboratory automation, and wider screening access. Newborn screening represents approximately 45% of application demand, creating a strong area for investment in screening systems and follow-up services. Point-of-Care Tests account for nearly 24% of testing methods and offer opportunities in regions with limited laboratory infrastructure. Molecular and genetic testing adoption exceeds 30% in advanced diagnostic centers, supporting investment in specialized platforms.

Further opportunities exist in emerging markets where testing coverage remains below potential levels. Asia-Pacific represents approximately 28% of global market demand, while Middle East & Africa contributes around 12%, creating room for new diagnostic centers, decentralized testing, and community screening programs. Family and carrier testing contribute nearly 30% of application activity, providing another investment area. Companies developing low-complexity testing systems, portable platforms, and integrated laboratory solutions may benefit from rising healthcare access.

New Products Development

New product development in the Sickle Cell Anemia Testing & Screening Market is focused on faster results, easier operation, improved accuracy, and wider testing access. Point-of-Care Tests account for approximately 24% of testing methods, encouraging manufacturers to develop compact and simple screening systems. Molecular testing adoption is above 30% in advanced diagnostic centers, supporting the development of improved genetic and confirmatory platforms. Automated laboratory systems are also expanding, with automation approaching 35% of advanced testing workflows.

New screening products are also being designed for newborns, community programs, and locations with limited laboratory resources. Newborn Screening represents about 45% of application demand, creating a major product development area. Portable testing systems can support decentralized screening, while digital connectivity can improve reporting and follow-up. More than 25% of modern laboratory workflows are increasingly linked with digital reporting or electronic data handling. Manufacturers are also developing systems that combine screening and confirmation functions, which may help reduce testing delays and improve patient referral.

Recent Developments

• Expansion of rapid screening platforms: Manufacturers continued improving rapid screening technologies in 2024, with Point-of-Care Tests representing approximately 24% of testing methods and supporting faster testing in decentralized healthcare settings.
• Improved hemoglobin analysis systems: Testing manufacturers enhanced systems used for hemoglobin analysis, supporting the growing use of detailed laboratory testing. Advanced testing centers now account for more than 30% adoption of molecular and specialized methods.
• Greater laboratory automation: Manufacturers increased automation features in diagnostic workflows during 2024, with automated processes approaching 35% of activity in advanced laboratories and helping reduce manual testing steps.
• Development of portable testing solutions: Portable diagnostic products received greater attention as manufacturers targeted underserved areas. Decentralized testing accounts for more than 20% of activity in selected healthcare settings with limited laboratory access.
• Digital reporting improvements: Manufacturers expanded connectivity and digital reporting features to improve laboratory workflows. Digital reporting is used in more than 25% of selected testing workflows, supporting faster result management and follow-up.

Report Coverage

The Sickle Cell Anemia Testing & Screening Market report covers major testing methods, applications, regional markets, competitive activity, market drivers, restraints, opportunities, challenges, investment areas, and product development. The analysis includes Hemoglobin Electrophoresis, High-performance Liquid Chromatography, Point-of-Care Tests, and Other Test methods. Application coverage includes Newborn Screening, Adult Screening, and Other Age Groups. Newborn Screening represents approximately 45% of application demand, while laboratory-based testing accounts for more than 70% of routine testing activity. Regional coverage includes North America, Europe, Asia-Pacific, and Middle East & Africa, together representing 100% of the assessed market. The report also reviews screening access, laboratory automation, molecular testing, family screening, and diagnostic awareness.

SWOT analysis identifies strong laboratory infrastructure and established screening programs as key strengths, with more than 70% of routine testing supported by laboratory methods. Opportunities include expanding Point-of-Care Tests, which account for about 24% of testing methods, and increasing molecular testing adoption above 30% in advanced centers. Weaknesses include uneven access to specialized testing, while challenges include awareness gaps affecting nearly 30% of some underserved populations and specialist shortages exceeding 25%. These factors influence competition, product development, investment, and regional market expansion.

Future Scope

The future scope of the Sickle Cell Anemia Testing & Screening Market is closely linked to early diagnosis, wider newborn screening, portable testing, molecular analysis, and digital laboratory systems. Newborn Screening currently represents approximately 45% of application demand, creating continued opportunities for automated and easy-to-use screening platforms. Point-of-Care Tests account for nearly 24% of testing methods and are expected to remain important for decentralized healthcare. Molecular and genetic testing adoption above 30% in advanced diagnostic centers also creates opportunities for more precise confirmation and carrier identification. Manufacturers are likely to focus on faster workflows, simpler sample handling, and better result management.

Regional expansion will remain important, particularly in Asia-Pacific and Middle East & Africa, which together represent approximately 40% of the global market. Increasing healthcare access, community screening, family testing, and public-health programs can improve testing coverage in these regions. Digital reporting, laboratory automation, and connected diagnostic platforms are also expected to gain importance, with automation already approaching 35% in advanced facilities. Family and carrier screening, representing nearly 30% of application activity, offers another area for future development. Products that combine affordability, portability, reliable results, and simple operation are likely to have strong relevance as screening programs expand.